Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Human Genome Sciences second-quarter revenues increase to $38.8 million

Human Genome Sciences, Inc. today announced financial results for the quarter ended June 30, 2010, and provided highlights of recent key developments.

23 Jul 2010

Unapproved cyanide antidote kits seized from Keystone Pharmaceuticals

At the request of the U.S. Food and Drug Administration, U.S. Marshals today seized $39,000 worth of products labeled as cyanide antidote kits from Keystone Pharmaceuticals in Laguna Hills, California. The seizure warrant was issued by the U.S. District Court for the Central District of California.

23 Jul 2010

Vascular Solutions second-quarter net income increases 6% to $1.475M or 0.09 per diluted share

Vascular Solutions, Inc. today reported financial results for the second quarter ended June 30, 2010.

23 Jul 2010

Endologix second-quarter total revenue increases 19% to $15.7 million

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2010.

23 Jul 2010

Researchers share nanotechnology knowledge

InForm, a AU$2.7 million EU-funded project involving world-leading research institutionsincluding the University of Sydney,hosted its first conference, 'NanoFormulation2010', in June at Stockholm University.

22 Jul 2010

Sigma-Aldrich second-quarter sales increase 6% to $554 million

Commenting on second quarter 2010 performance, Chairman, President and CEO Jai Nagarkatti said: "Our earnings for the second quarter of 2010 continued the strong performance achieved in this year's first quarter. We are very pleased with this performance that drove our increase in diluted EPS for the first half of 2010 to 18%. Consistent with our first quarter 2010 experience, conditions were favorable in several of our markets.

22 Jul 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan Corporation, plc today reported its second quarter and first half 2010 financial results.

22 Jul 2010

LBL signs strategic partnership agreement with Proliant

Lampire Biological Laboratories announced today that it signed an agreement with Proliant Health and Biologicals, manufacturer of the worlds most trusted, high quality Bovine Serum Albumin, to do contract filling & provide BSA to customers requiring less than Proliant's standard 10 kilogram packaging. Lampire will also offer made-to-order aqueous blends in buffers and package sizes to customer specifications.

22 Jul 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010. The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million. Net loss, excluding a restructuring charge of $3.4 million, was $40.8 million, or $0.28 per share.

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

IQPC presents summit for better implementation of PAT & QbD initiatives

IQPC presents the 4th PAT Summit: Implementing PAT & QbD for Improved Quality and Cost Savings, taking place September 13 - 15 in Philadelphia. In today's marketplace manufacturers are challenged to improve quality while simultaneously reducing development and production cost.

From IQPC Ltd 22 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

KMSA to host 3D laser scanning open house and medical device workshop

Konica Minolta Sensing Americas, Inc., the worldwide leader in the industrial measurement of color, light and shape, announces its 3D laser scanning open house and medical device workshop July 28, 2010 to be held in its state of the art 3D scanning lab in Ramsey, NJ.

21 Jul 2010

Mesoblast gains Australian TGA licence to manufacture Mesenchymal Precursor Cell products

Australian regenerative medicine company, Mesoblast Limited, today announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cell (MPC) products.

21 Jul 2010

Sinobiopharma, Xianfeng enter agreement to manufacture, co-market Clindamycin and L-alanyl-L-glutamine

Sinobiopharma, Inc. is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.

21 Jul 2010

CSIRO signs global licensing agreement for Reversible Addition-Fragmentation chain Transfer technology

CSIRO has signed a global licensing agreement for its patented RAFT technology. Reversible Addition-Fragmentation chain Transfer (or RAFT) technology is an elegant and powerful polymerisation process that has given rise to a new branch of polymer chemistry.

21 Jul 2010

New development in flu prevention & treatment

In a groundbreaking development, scientists at the Australian National University in Canberra have found the key to the mutation of the flu virus. This may allow the manufacturing of a life-long vaccine stopping the need for repeated vaccinations. The scientists reveal that they have found a protein in the virus that changes or mutates in order to develop resistance in the virus.

20 Jul 2010

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

International Stem Cell Corporation, www.internationalstemcell.com, and Insight Bioventures India Private Limited, announced today that they have signed a letter of intent concerning funding and establishment of an Indian affiliate of ISCO. The goal is to establish world-class development and manufacturing operations for ISCO's research and pharmaceutical products in India, including its Lifeline Cell Technology research products and human corneal tissue, CytoCor, for treatment of corneal vision impairment and testing of chemicals.

20 Jul 2010

Inergetics receives CPR to market Resurgex Select product as nutritional supplement

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has received a Certificate of Product Registration from the FDA Philippines, certifying that its Resurgex Select product can now be marketed as a nutritional supplement for cancer patients and other immune-compromised individuals throughout the country.

20 Jul 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

20 Jul 2010